TRIAL COMPARING 5-FU PLUS LEUCOVORIN AND OXALIPLATIN IN CARCINOMA OF THE COLON

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Colorectal cancer is the third most common cause of death from malignancy in both males and females in the U.S. Although surgery remains the mainstay of treatment for stage II and III colorectal cancer, it is curative only in some patients. Studies from the NSABP and other cooperative groups have clearly demonstrated that adjuvant chemotherapy has altered the natural history for patients with stage II and III colorectal cancer. Two approaches have resulted in improvement in disease-free survival (DFS) and survival (S). Despite adjuvant chemotherapy, about one-third of patients with colorectal cancer will develop a recurrence within five years of surgery. Thus, there continues to be a need to evaluate new treatments for this disease. New treatment strategies and more effective drugs or combinations of drugs are needed to further improve outcome in these individuals. The hypothesis for this trial is that an effective first-line advanced colorectal cancer treatment may improve disease-free survival and overall survival in the adjuvant setting. Oxaliplatin has demonstrated clinical synergism with 5-FU + LV in randomized clinical trials. It is appropriate to evaluate the efficacy of the combination in an adjuvant setting.